Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

March 23, 2026

NEW IPSOS SURVEY REVEALS MAJORITY (72%) OF CANADIAN MOMS FEEL JUDGED FOR NOT COOKING FROM SCRATCH

March 23, 2026

2 Air Canada pilots dead after flight from Montreal crashes at LaGuardia Airport

March 23, 2026

BLAQclouds, Inc. Announces The Successful Automation of Major Payment Platforms on ApolloCASH and Phase One Rollout of theAlley.io

March 23, 2026

OwlTing Group (NASDAQ: OWLS) Recognized Among Financial Times Top 500 High-Growth Companies in Asia-Pacific 2026

March 23, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Shingles Vaccine Market Analysis 2024-2034: Dominated by Ethicon, 3D Systems, Medacta, Simulab Corporation, and InSilicoTrials
Press Release

Shingles Vaccine Market Analysis 2024-2034: Dominated by Ethicon, 3D Systems, Medacta, Simulab Corporation, and InSilicoTrials

By News RoomJanuary 25, 20243 Mins Read
Shingles Vaccine Market Analysis 2024-2034: Dominated by Ethicon, 3D Systems, Medacta, Simulab Corporation, and InSilicoTrials
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) — The “Global Shingles Vaccine Market Analysis & Forecast 2024-2034” report has been added to ResearchAndMarkets.com’s offering.

This industry analysis on the shingles vaccine market projects a significant expansion, with an estimated compound annual growth rate (CAGR) of 9.96% from 2024 to 2034. Current data indicates that the market, valued at $3.43 billion in 2023, is expected to achieve an impressive $9.75 billion by the end of the forecast period. Factors propelling this growth include an aging population, advancements in healthcare policies, and increased approvals for new shingles vaccinations.

An Aging Population Drives Demand for Shingles Vaccination

The rising global incidence of shingles, especially among individuals over 60, has become a catalyst for market expansion. As healthcare initiatives progress, there is a visible shift toward innovative recombinant vaccines that offer effective protection against the herpes zoster virus, which causes shingles.

New Shingles Vaccine Approvals Spur Market Advancements

Regulatory approvals are critical for the distribution and use of new shingles vaccines. Recent approvals in various regions underscore the demand for effective immunization options against this pervasive disease.

Increasing Prevalence of Herpes Zoster Cases

The market is witnessing heightened activity, with an upward trend in herpes zoster cases globally. This increase underscores the importance of shingles vaccinations as a preventive healthcare measure.

  • Product Segment Analysis: Shingrix, as a high-efficacy vaccine, continues to dominate the market, supported by the rising awareness and growing adoption of this innovative vaccination.
  • Vaccine Type Segment Analysis: Recombinant vaccines have emerged as a significant revenue-contributor due to their efficacy and the ongoing efforts to develop newer vaccines.
  • End-user Segment Analysis: Hospitals, with their extensive reach and infrastructure, lead the end-user segment thanks to an uptick in the number of shingles cases and a more informed elderly population.

The North American market is set to maintain its dominance, bolstered by favorable reimbursement scenarios, heightened disease awareness, and strong vaccine adoption rates. Furthermore, advancements like mRNA vaccine trials are contributing to this regional market’s strength. Meanwhile, the Asia Pacific region is forecasted to exhibit the fastest CAGR in the coming years. Factors such as rising disposable incomes, improved healthcare policies, and the growing acceptance of vaccines like Shingrix drive this remarkable growth trend.

Market Segmentation Insights

A comprehensive segmentation analysis reveals the diverse product types, vaccine classifications, and end-user groups interacting within the global shingles vaccine market. It outlines key areas like the live attenuated and recombinant vaccines, as well as specific end-user sectors including hospitals and specialty clinics.

Regional Market Dynamics

In-depth regional insights highlight market dynamics in North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa. The report provides extensive coverage of both established and emerging markets, creating a robust picture of the global shingles vaccine landscape.

Key Attributes

Report Attribute Details
No. of Pages 200
Forecast Period 2023-2034
Estimated Market Value (USD) in 2023 $3.43 Billion
Forecasted Market Value (USD) by 2034 $9.75 Billion
Compound Annual Growth Rate 9.9%
Regions Covered Global

Companies Mentioned

  • Ethicon
  • 3D Systems
  • Medacta
  • Simulab Corporation
  • InSilicoTrials
  • Inovus Medical
  • Mentice AB
  • Simulaids
  • Limbs & Things Ltd.
  • Laerdal Medical
  • Surgical Science Sweden AB

For more information about this report visit https://www.researchandmarkets.com/r/1e4cf6

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • Global Shingles Vaccine Market

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

NEW IPSOS SURVEY REVEALS MAJORITY (72%) OF CANADIAN MOMS FEEL JUDGED FOR NOT COOKING FROM SCRATCH

BLAQclouds, Inc. Announces The Successful Automation of Major Payment Platforms on ApolloCASH and Phase One Rollout of theAlley.io

OwlTing Group (NASDAQ: OWLS) Recognized Among Financial Times Top 500 High-Growth Companies in Asia-Pacific 2026

PyroGenesis’ Plasma-Based SPARC™ System Officially Unveiled at Launch of New Zealand’s National Refrigerant Destruction Facility

Q2 Metals Announces Multiple 200+ Metre Intervals of Continuous Spodumene Pegmatite and Provides an Update on the Inaugural Mineral Resource Estimate at the Cisco Lithium Project, Quebec, Canada

Algernon to Open the First Brain Dedicated PET Scanning Clinic in the U.S. at the HCA Florida University Medical Office Building 

Abaxx Exchange Reports Record Weekly Trading Volume

FuelCell Energy Scales Up for Data Centers with Packaged 12.5 MW Utility‑Grade Power Block Solution and Manufacturing Expansion Plans

Editors Picks

NEW IPSOS SURVEY REVEALS MAJORITY (72%) OF CANADIAN MOMS FEEL JUDGED FOR NOT COOKING FROM SCRATCH

March 23, 2026

2 Air Canada pilots dead after flight from Montreal crashes at LaGuardia Airport

March 23, 2026

BLAQclouds, Inc. Announces The Successful Automation of Major Payment Platforms on ApolloCASH and Phase One Rollout of theAlley.io

March 23, 2026

OwlTing Group (NASDAQ: OWLS) Recognized Among Financial Times Top 500 High-Growth Companies in Asia-Pacific 2026

March 23, 2026

Latest News

PyroGenesis’ Plasma-Based SPARC™ System Officially Unveiled at Launch of New Zealand’s National Refrigerant Destruction Facility

March 23, 2026

Q2 Metals Announces Multiple 200+ Metre Intervals of Continuous Spodumene Pegmatite and Provides an Update on the Inaugural Mineral Resource Estimate at the Cisco Lithium Project, Quebec, Canada

March 23, 2026

Algernon to Open the First Brain Dedicated PET Scanning Clinic in the U.S. at the HCA Florida University Medical Office Building 

March 23, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version